Back to News
Market Impact: 0.25
Hemab Doses First Participant In Phase 1 HMB-003 Trial For Heavy Menstrual Bleeding
Source: Nasdaq
Healthcare & BiotechProduct Launches
Hemab Therapeutics (COAG) dosed the first participant in its Phase 1 trial of HMB-003, an investigational peptide therapy for heavy bleeding associated with blood coagulation disorders. The milestone advances the company’s clinical-stage pipeline, though efficacy and safety data remain pending.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
COAG0.45
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Citizens reiterates Ondas Holdings stock rating on IonStrike updates
- Apple’s new CEO Ternus to face first earnings test as memory costs surge
- Deutsche Bank downgrades Novartis stock rating to sell on valuation
- Apple, Marriott International and 3 Stocks to Watch Heading Into Monday
- Soaring health insurance costs are quietly preventing wages from rising higher, while workers also shoulder a larger share of premiums, economist says